Search the site

Community and Food Environments study

Gina Nicole Trapp Hanna BHSc(Hons1A), RPHNutr, PhD BHlthSc (Hons) Honorary Research Associate Program Manager 08 6319 1033 Gina.Trapp@thekids.org.au

Wellbeing and Type 1 Diabetes

A community-led, trauma-informed psychosocial intervention to improve health outcomes of children and young people with Type-1 diabetes.

Co-designing a trauma-informed program for parents whose infant has had a Neonatal Intensive Care Unit (NICU) admission

Having a newborn child admitted into a NICU can be highly traumatic for parents. The compounding effects of the NICU clinical environment, having a seriously ill child, in addition to the inability to care or adequately bond with your child can be extremely distressing.

COMBAT CF: A phase 3 multi-centre randomized placebo-controlled study of azithromycin in the primary prevention of radiologically-defined bronchiectasis in infants with cystic fibrosis.

A phase 3 multi-centre randomized placebo-controlled study of azithromycin in the primary prevention of radiologically-defined bronchiectasis in infants with cystic fibrosis

SHIP CT: A Phase 3 randomised, double-blind, controlled trial of inhaled 7% hypertonic saline versus 0.9% isotonic saline for 48 weeks in patients with Cystic Fibrosis at 3-6 years of age in parallel with the North American SHIP clinical trial.

SHIP-CT, led by Professor Stephen Stick, Director of the Wal-yan Respiratory Research Centre at The Kids, is a unique study in preschool-aged children (from 3-6 years of age) with CF using images of the lung from chest CT scans as the main outcome measure.

FASD Hub Australia

The FASD Hub brings together the latest evidence-based content about alcohol, pregnancy and Fetal Alcohol Spectrum Disorder (FASD) in Australia.

Home

Cultures of HRV-C for investigations of pathogenesis in children

Anthony Belinda Ingrid Kicic Hales Laing BSc (Hons) PhD BSc (Hons) PhD BSc PhD Rothwell Family Fellow; Head, Airway Epithelial Research Senior

Multigenerational Familial and Environmental Risk for Autism (MINERvA) Network

The MINERvA Network will allow more accurate and precise determination of the contributions of familial and environmental factors to the etiology of autism.

A phase IIIB, randomized, controlled, observer-blind study to evaluate safety and immunogenicity of GSK’s meningococcal ABCWY vaccine when administered in healthy adolescents and adults, previously primed with meningococcal ACWY vaccine (BOOST)

Investigator: Peter Richmond Project description GSK is conducting a research study to evaluate its investigational, pentavalentmeningococcal vaccine